Erasca, Inc. Common Stock
Symbol: ERAS (NASDAQ)
2.23
▼ (-6.47%) -0.154
Company Description:
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Key Stats
- Today's Open: $2.38
- Today's High: $2.415
- Today's Low: $2.205
- Today's Volume: 1.32M
- Yesterday Close: $2.38
- Yesterday High: $2.49
- Yesterday Low: $2.35
- Yesterday Volume: 1.05M
- Last Min Volume: 1
- Last Min High: $2.243
- Last Min Low: $2.226
- Last Min VWAP: $2.24
Company Profile
- Name: Erasca, Inc. Common Stock
- Website: https://www.erasca.com
- Listed Date: 2021-07-16
- Location: SAN DIEGO, CA
- Market Status: Active
- CIK Number: 0001761918
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $675.13M
- Round Lot: 100
- Outstanding Shares: 283.67M
- Asset Type: CS
RECENT FILINGS FOR ERAS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-15 | 144 | View |
| 2025-09-15 | 144 | View |
| 2025-08-22 | EFFECT | View |
| 2025-08-20 | CORRESP | View |
| 2025-08-18 | UPLOAD | View |
| 2025-08-15 | 144 | View |
| 2025-08-14 | SCHEDULE 13G | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-13 | SCHEDULE 13G | View |
| 2025-08-12 | S-3 | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-12 | 8-K | View |
| 2025-07-15 | 144 | View |
| 2025-06-26 | 8-K | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
| 2025-06-26 | 4 | View |
Latest News on ERAS